{"id":295310,"date":"2025-02-03T00:00:00","date_gmt":"2025-02-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0002-2023-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need\/"},"modified":"2026-04-29T23:11:40","modified_gmt":"2026-04-29T23:11:40","slug":"unneop0002-2025-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need-geographic-atrophy-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0002-2025-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need-geographic-atrophy-us-eu\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Unmet Need &#8211; Unmet Need &#8211; Geographic Atrophy (US\/EU)"},"content":{"rendered":"<p><span>Geographic<\/span> atrophy (<abbr title=\"geographic atrophy\">GA<\/abbr>) is an advanced stage of age-related macular degeneration characterized by the progressive and irreversible degeneration of retinal tissue, including photoreceptors. This condition leads to a gradual loss of central vision, significantly affecting patients\u2019 daily activities and independence. The introduction of the first therapies approved for <abbr title=\"geographic atrophy\">GA<\/abbr>, Apellis\u2019s Syfovre (pegcetacoplan) and Astellas\u2019s Izervay (avacincaptad pegol), in the United States in 2023 revolutionized the treatment landscape. These intravitreal complement system inhibitors offer new therapeutic options beyond traditional over-the-counter vitamin supplements (i.e., <abbr title=\"Age-Related Eye Disease Study\">AREDS<\/abbr> 1 and <abbr title=\"Age-Related Eye Disease Study\">AREDS<\/abbr> 2). However, they face intensifying competition as numerous companies advance <abbr title=\"geographic atrophy\">GA<\/abbr> therapies in their pipelines and explore novel mechanisms of action. Understanding the factors that influence physicians\u2019 choice of therapy for <abbr title=\"geographic atrophy\">GA<\/abbr> and identifying the key areas of unmet need in the treatment of this disease will be crucial to the strategic positioning of novel agents in this rapidly evolving market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the most important factors driving ophthalmologists\u2019 prescribing decisions for <abbr title=\"geographic atrophy\">GA<\/abbr>? Do these factors differ between U.S. and European ophthalmologists?<\/li>\n<li>How do U.S. ophthalmologists perceive Syfovre and Izervay performing on key clinical attributes for <abbr title=\"geographic atrophy\">GA<\/abbr>? How different is their clinical performance compared with that of the <abbr title=\"Age-Related Eye Disease Study\">AREDS<\/abbr> supplements, according to ophthalmologists?<\/li>\n<li>What are the prevailing areas of unmet need in <abbr title=\"geographic atrophy\">GA<\/abbr>?<\/li>\n<li>What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new <abbr title=\"geographic atrophy\">GA<\/abbr> therapy?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> Survey of 61 U.S. and 30 European ophthalmologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Syfovre, Izervay<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature:<\/strong> The Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-295310","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295310\/revisions"}],"predecessor-version":[{"id":382638,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295310\/revisions\/382638"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}